<DOC>
	<DOCNO>NCT02785900</DOCNO>
	<brief_summary>The purpose study AML patient test whether vadastuximab talirine ( SGN-CD33A ; 33A ) combine either azacitidine decitabine extend overall survival longer placebo combine either azacitidine decitabine .</brief_summary>
	<brief_title>Vadastuximab Talirine ( SGN-CD33A ; 33A ) Combined With Azacitidine Decitabine Older Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>Hypomethylating agent ( HMAs ) , decitabine azacitidine , consider standard treatment old patient AML . The primary goal study test whether patient treat HMA ( either decitabine azacitidine ) combination 33A survive long patient treat HMA combination placebo . Patients meet eligibility criterion randomly assign one two treatment group : 1 ) 33A plus HMA ( Experimental Arm ) ; 2 ) placebo plus HMA ( Comparator Arm ) . In addition evaluate survival , remission rate , duration remission , event free- leukemia-free survival , safety tolerability compare arm .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Newly diagnose , previously untreated , cytologically/histologically confirm de novo secondary AML accord World Health Organization ( WHO ) classification ( except acute promyelocytic leukemia ( APL ) ) Intermediate adverse cytogenetic risk Eligible therapy either decitabine azacitidine Acceptable hematologic organ function AML associate favorable risk karyotype include inv ( 16 ) , ( 8 ; 21 ) , ( 16 ; 16 ) , ( 15 ; 17 ) Patients candidate allogeneic stem cell transplant time enrollment Patients history one follow myeloproliferative neoplasm : essential thrombocythemia , polycythemia vera , primary myelofibrosis Received prior treatment HMA chemotherapy antecedent myelodysplastic syndrome ( MDS )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Antibodies , monoclonal</keyword>
	<keyword>Antibody drug conjugate</keyword>
	<keyword>Antigens , cluster differentiation 33 ( CD33 )</keyword>
	<keyword>Drug therapy</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>